Regenerative Treatment Evidence: How to Read It

Regenerative treatment evidence is the heading most often skipped and the one most useful when deciding. In this field the marketing usually runs ahead of the evidence, which leaves patients unsure what to trust. This article covers how to read the evidence and what to look at.

What does level of evidence mean?

Short answer: What kind of study a claim rests on. A laboratory observation and a controlled study in people do not carry the same weight.

That ranking is medicine's own internal logic. Cell culture and animal studies sit at the bottom; controlled studies in people and reviews of those sit above them.

For some of the treatments gathered under the regenerative heading, the available data still sits on the lower rungs. That does not mean the treatment does not work; it means it is not yet known.

The difference matters. "It does not work" and "it has not been studied enough" are not the same sentence, and using one for the other is misleading.

Why is there no institutional page?

The most practical indicator in this field is whether institutional patient information pages exist. Bodies like the NHS and the AAD publish patient guides once the evidence reaches a certain maturity.

For exosomes and polynucleotides no such page exists. That is not a failure of searching; it is the real state of the field, and saying so is part of being honest.

Regulatory warnings do exist, though. In the US the FDA publishes a consumer alert about unapproved products containing stem cells and exosomes and states plainly that marketing claims run ahead of the evidence.

That alert belongs to US regulation. In Turkey licensing sits with TITCK, and that distinction is stated rather than blurred.

Which sentences are warning signs?

Short answer: Sentences that give a definite rate, that say "proven", and that offer one treatment for every complaint. All three claim more than the evidence can carry.

Sentences with numbers come first. A promise of a specific percentage or session count shows that variables belonging to the person were not weighed at all.

The second is scope. Offering one treatment with equal certainty for hair loss, skin ageing and something else again is marketing language rather than evidence.

The third is the stem cell association. That phrase is used often and frequently does not match the product being applied; we covered stem cell aesthetics claims separately.

What should a patient look at?

Short answer: The product and its licensing, the language the doctor uses, whether alternatives with stronger evidence are discussed, and how the expectation is described.

The product comes first. The name, licensing status and contents of what will be used can be asked about, and having the box opened in front of you is ordinary practice.

The second is language. A doctor avoiding definite sentences, stating uncertainty openly and describing the limits reads as a positive sign rather than a lack of confidence.

The third is alternatives. Where options with stronger evidence exist for the same complaint, those should be discussed too. We covered what regenerative treatment is separately.

Why does evidence move slowly here?

The first reason is definition. Substances and treatments that differ from each other are gathered under one "regenerative" heading, and things grouped together still have to be studied separately.

The second is product variety. Products sold under the same name differ in content, preparation and concentration between manufacturers, so a result obtained with one does not transfer to another.

The third is measurement. Headings like skin quality or hair density are hard to measure objectively, and studies use different methods.

The fourth is time. Treatments that give gradual results need long follow-up, which makes studies expensive to run.

Does no evidence mean no treatment?

This is not a binary question. A low level of evidence does not mean the treatment never comes up; it means the expectation and the language are built accordingly.

What decides is the safety side. Whether known harm has been reported, whether the product is licensed and whether the conditions are appropriate are headings separate from and prior to the evidence discussion; we covered exosome product safety separately.

The second decisive factor is choice. Someone who receives the information in full making their own decision is a different thing from being steered while information is withheld.

The third is record-keeping. If the product name and date are kept, an assessment can be made later against a new finding or new data. What happens in the days after a session is covered in aftercare after PRP. The scope of the treatment sits on the exosome therapy page.

Frequently asked questions

What does "supported by clinical studies" mean? On its own it says nothing. Without answers to which study, in how many people, over how long and compared against what, the phrase carries no information. Because it appears so often in product marketing, it is not read as a reassurance in itself.

Is being used abroad enough? It is not. A product being used in another country does not show what status it was approved under there; cosmetic, medical device and medicine categories go through different processes. In Turkey the licence that counts is issued by TITCK, and that is what to ask about.

Does the evidence change over time? It does, and in this field it is expected to. A treatment sitting on a lower rung today may be supported by stronger data later; the reverse is possible too. That is why the decision is made with today's information and keeping a record of the product used helps later.

---

If you would like to talk through the evidence status of a treatment and whether it suits you, a consultation is the place to discuss it.

This content is for informational purposes only and does not replace a medical consultation.